Document is current
Any future updates will be listed below
-
Authors
Fromer, Menachem https://orcid.org/0000-0003-3749-4342
Roussos, Panos
Sieberts, Solveig K
Johnson, Jessica S
Kavanagh, David H
Perumal, Thanneer M
Ruderfer, Douglas M
Oh, Edwin C
Topol, Aaron
Shah, Hardik R
Klei, Lambertus L
Kramer, Robin
Pinto, Dalila https://orcid.org/0000-0002-8769-0846
Gümüş, Zeynep H
Cicek, A Ercument
Dang, Kristen K
Browne, Andrew
Lu, Cong
Xie, Lu
Readhead, Ben
Stahl, Eli A
Xiao, Jianqiu
Parvizi, Mahsa
Hamamsy, Tymor
Fullard, John F
Wang, Ying-Chih
Mahajan, Milind C
Derry, Jonathan M J
Dudley, Joel T
Hemby, Scott E
Logsdon, Benjamin A https://orcid.org/0000-0002-0572-2569
Talbot, Konrad
Raj, Towfique
Bennett, David A
De Jager, Philip L
Zhu, Jun
Zhang, Bin
Sullivan, Patrick F https://orcid.org/0000-0002-6619-873X
Chess, Andrew
Purcell, Shaun M
Shinobu, Leslie A
Mangravite, Lara M https://orcid.org/0000-0001-7841-3612
Toyoshiba, Hiroyoshi
Gur, Raquel E
Hahn, Chang-Gyu
Lewis, David A
Haroutunian, Vahram
Peters, Mette A
Lipska, Barbara K
Buxbaum, Joseph D
Schadt, Eric E
Hirai, Keisuke
Roeder, Kathryn
Brennand, Kristen J
Katsanis, Nicholas
Domenici, Enrico
Devlin, Bernie
Sklar, Pamela
- License Information
-
More Information
Article History
Received: 5 May 2016
Accepted: 1 September 2016
First Online: 26 September 2016
Competing interests
: E. Dominici was an employee of F. Hoffmann-La Roche for the first portion of the study and later served as a consultant to Roche in the area of genetic biomarkers. H. Toyoshiba and K. Hirai are employees of Takeda Pharmaceutical Company Limited and L.A. Shinobu is a former employee. D.A.L. currently receives investigator-initiated research support from Pfizer and from 2012 to 2014 served as a consultant in the areas of target identification and validation and new compound development to Autifony, Bristol-Myers Squibb, Concert Pharmaceuticals and Sunovion. M. Fromer was an employee of Mount Sinai until April 2016; he is now an employee of Google Verily.
